Third COVID-19 vaccine dose could improve protection in transplant recipients
The results from the first COVID-19 vaccine booster trial in transplant recipients show a third dose is safe and highly immunogenic.
List view / Grid view
The results from the first COVID-19 vaccine booster trial in transplant recipients show a third dose is safe and highly immunogenic.
Moderna and the Canadian government are collaborating to build an mRNA vaccine manufacturing facility in Canada.
The global cell and gene therapy manufacturing services market is expected to grow at a CAGR of 12.4 percent in the next five years.
In this whitepaper, C2C’s Product & Process Development Lead explains how using digital modelling in the design process can guarantee results.
New report suggests the cell line development services market will witness a 14.3 percent CAGR between 2021 and 2030.
Moderna tops the 2021 Best Workplaces for Innovators list following its "epic" COVID-19 vaccine development journey and impressive growth in 2020.
Results from the NOVA study show every six-week dosing with natalizumab is as effective as every four-week in relapsing-remitting MS.
Moderna’s mRNA respiratory syncytial virus (RSV) vaccine candidate, mRNA-1345, gains Fast Track designation in adults over 60 years old.
Learn how you can go about changing QC test methods and how this can go a long way to helping your lab achieve data integrity compliance.
H1 financial results show AstraZeneca’s revenues grew by 23 percent in 2021, with $14.37 billion attributed to activities aside from COVID-19 vaccine sales.
3 August 2021 | By Thermo Fisher Scientific
In this on-demand webinar, discover the differences between FTIR, NIR and Raman spectroscopy, learn how spectroscopy is applied in quality control labs and hear how implementation of these techniques increased efficiency and minimised costs.
A new approach to the cost-comparison fast-track appraisal process is being piloted this summer for the review of low-risk appraisals.
The FDA have authorised REGEN-COV monoclonal antibody therapy for emergency use as prevention for COVID-19 in certain patients.
This article addresses early planning for paediatric evaluation of certain molecularly targeted oncology drugs, including biological products, for which original New Drug Application (NDAs) and Biological License Application (BLAs) are expected to be submitted to FDA, in accordance with The FDA Reauthorization Act (FDARA).
Live biotherapeutic products (LBPs) are expected to help patients with IBS who currently have no US- or EMA-approved treatments.